GRHPR Carrier on 23andMe? What a Single Primary Hyperoxaluria Type 2 Variant Really Means

GRHPR Carrier on 23andMe? What a Single Primary Hyperoxaluria Type 2 Variant Really Means

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

Bottom line: Research shows primary hyperoxaluria is a rare autosomal recessive disease. A single GRHPR carrier result means you are almost certainly healthy, not affected. Genetic studies confirm the disease needs two faulty copies, not one. The variant matters most for family planning and for relatives with unexplained kidney stones.

What you’ll learn:

• Why one GRHPR variant makes you a carrier, not a patient
• The real, absolute odds that your children could be affected
• How primary hyperoxaluria is actually diagnosed and confirmed
• The honest, dated facts about new RNAi drugs and whether they apply to the GRHPR (type 2) form

How Primary Hyperoxaluria Is Inherited: The GRHPR Gene and Recessive Transmission

Primary hyperoxaluria is a group of rare metabolic disorders. In each type, the liver overproduces a chemical called oxalate. The extra oxalate binds calcium and forms crystals that harm the kidneys. Think of oxalate like sand in a water pipe: a little washes through, but too much clogs the system. Over years, those crystals build kidney stones and hard calcium deposits.

Studies describe three types, sorted by which gene is broken. Your 23andMe report flagged GRHPR, so it points to type 2. Here is how the three subtypes compare:

Type	Broken gene	Broken enzyme step	Typical severity
PH1	AGXT	alanine-glyoxylate aminotransferase	Most common; generally most severe
PH2	GRHPR	glyoxylate reductase/hydroxypyruvate reductase	Usually milder, but not benign
PH3	HOGA1	4-hydroxy-2-oxoglutarate aldolase	About 10% of cases

The GRHPR gene carries instructions for an enzyme with a long name, glyoxylate reductase/hydroxypyruvate reductase. That enzyme normally helps the body break down a molecule called glyoxylate. When both gene copies fail, glyoxylate breakdown drops and the liver makes too much oxalate. The gene sits on chromosome 9, and the disease appears only with two faulty copies.

All three types follow autosomal recessive inheritance. That phrase means a person needs two faulty copies of the same gene, one from each parent, to develop the disease. A carrier has one working copy and one faulty copy. Research confirms that parents of an affected child are typically unaffected carriers, and PH2 in particular appears only with two faulty GRHPR copies. In everyday terms, one good copy still does the job, much like a car that runs fine on a single working headlight bulb.

One detail from the genetics literature is worth knowing. Certain GRHPR variants are more common in specific ancestry groups, sometimes called founder variants. For example, one deletion recurs in people of Northern European or American background, and another in people of Japanese or Chinese origin. That is why a limited panel can catch some variants and miss others.

PH2, the GRHPR type your report flagged, is usually milder than PH1, though clinical sources stress it is not benign and can still cause recurrent stones and kidney damage. Knowing your report points to the milder type is genuinely reassuring context, even before any confirmation.

Here is the key point for your result. A 23andMe report checks only a small, fixed list of specific variants. So one flagged GRHPR variant shows carrier status, not disease. A “clear” report also cannot fully rule out carrier status, because the panel is limited. Only two confirmed faulty GRHPR copies, plus lab evidence of excess oxalate, define PH2. If any part of this worries you, a genetic counselor (find one at NSGC.org) can walk you through it calmly.

Section recap: Primary hyperoxaluria is recessive, and GRHPR points to type 2. One flagged variant makes you a carrier, not a patient.

Risk Magnitude: The Carrier Math and How Rare This Disease Really Is

Genetics can feel abstract, so let us turn it into plain numbers. As a single GRHPR carrier, your own risk of developing primary hyperoxaluria is essentially zero. Carriers do not get the disease from one variant. Your kidneys are not in danger simply because this variant showed up. This is the single most reassuring fact in your whole report.

Recurrence risk only becomes relevant if your reproductive partner also carries a GRHPR variant. If both partners are carriers, the odds for each pregnancy are fixed by classic inheritance rules:

• 25% chance of an affected child (about 25 out of 100 pregnancies)
• 50% chance of a carrier child (healthy, like you)
• 25% chance of a child with two working copies (not a carrier at all)

Those odds apply only when both parents carry a faulty copy. If your partner is not a carrier, the affected-child odds drop to essentially zero, though half of your children could still be carriers themselves.

How rare is this disease overall? Reviews put the traditional estimate at roughly 1 to 3 cases per million people. That is far below 1 in 100,000. PH1 is the most common form, while types 2 and 3 each make up about 10% of cases. So PH2 specifically is rarer still, a small slice of an already rare condition. Newer genetic estimates, drawn from large population databases such as gnomAD, suggest more people carry these variants than diagnosed cases imply, meaning the disease is likely underdiagnosed. The gap between genetic and clinical numbers hints that some affected adults, including people with recurrent stones, have never been correctly labeled.

It also helps to know PH2 is generally milder than PH1, though it is not harmless. A long-term cohort of 101 genetically confirmed PH2 patients showed a median age at first symptom of about 3 years, but many were not diagnosed until around age 8. That delay itself shows how easily the condition hides, even in truly affected people, let alone healthy carriers.

So treat a single carrier result as low-probability reproductive information, not a personal health emergency. The useful move is confirmation and context from a clinician, not alarm. Your primary care physician or a genetic counselor can help you weigh the numbers.

Section recap: One carrier variant means near-zero personal risk. The 25% figure applies only if both partners carry a GRHPR variant.

Testing Options: 24-Hour Urine, Plasma Oxalate, Gene Sequencing, and DTC Reports

A worried carrier in the US or Canada meets several very different tests. It helps to sort them into three groups by purpose:

• Biochemical testing — measures oxalate directly. A high level on a 24-hour urine collection is the classic first clue. When kidney function drops, doctors also measure oxalate in the blood (plasma oxalate). A nephrologist or urologist orders these, since interpreting them takes clinical training.
• Confirmatory genetic testing — targeted or panel sequencing of the AGXT, GRHPR, and HOGA1 genes in a certified clinical lab. In the US these are CLIA-certified labs; in Canada they are accredited labs. If gene testing finds no or only one faulty variant, measuring enzyme activity in a liver biopsy can still establish the diagnosis in older diagnostic pathways.
• Direct-to-consumer and clinical carrier panels — the group you already used: reports like 23andMe, plus panels from labs such as Invitae, Color, Labcorp, or Quest. These test a limited set of variants and are not diagnostic. A DTC report is a smoke detector, not a diagnosis: it can hint at fire, but a professional must confirm it.

For a healthy carrier with no symptoms, biochemical testing is not automatically needed; those tests belong to the workup of someone with stones or a strong suspicion of disease. Research on variant classification explains why labs must sort findings into tiers rather than give simple yes/no answers.

It helps to picture how these tests fit together in real life. A person with unexplained stones might first give a 24-hour urine sample, which reveals high oxalate. That result prompts gene sequencing of the three PH genes. If two clearly faulty GRHPR copies turn up, the picture points to PH2. If the genes are unclear, enzyme testing can fill the gap. No single test stands alone; the diagnosis is a case built from several pieces.

When would a doctor test for primary hyperoxaluria? Recurrent kidney stones that start in childhood are a strong reason, since cohort data show most PH2 patients first had symptoms as young children. So is a first stone paired with a suggestive family history. Because adults with recurrent stones can be undiagnosed, this matters for your brother too. Remember that genetic prevalence studies suggest a meaningful pool of undiagnosed adults exists. If your result feels concerning, ask a nephrologist or a genetic counselor at NSGC.org about the right confirmatory path.

Section recap: Biochemical and gene testing in certified labs confirm the disease; DTC reports only screen limited variants and need clinical follow-up.

Interpreting Your Result: Carrier vs Diagnosis vs Uncertain Variant

Three phrases get mixed up all the time, so let us separate them clearly:

• Carrier — one faulty GRHPR variant. The person is unaffected, and the result matters only for family planning. This is your situation as described.
• Diagnosis (PH2) — two faulty GRHPR copies, plus lab or clinical evidence of excess oxalate. A very different result from carrier status.
• Variant of uncertain significance (VUS) — a change in the gene that labs cannot yet classify as harmful or harmless.

Professional standards from the American College of Medical Genetics and Genomics, published in 2015, define five tiers: pathogenic, likely pathogenic, uncertain, likely benign, and benign. Those standards weigh many separate lines of evidence before a variant earns a label. The guideline is clear that a VUS should not by itself drive medical decisions. It is like a book still waiting to be shelved: you cannot judge it until it is properly filed.

This tiering explains something you may notice on different reports. One lab might call a change “pathogenic” while another calls the same change “uncertain,” because they weighed the evidence at different times. Variants can also be reclassified as knowledge grows. That is a normal part of genetics, not a mistake, and it is one more reason to have a clinician interpret a result rather than react to a single line on a printout.

One more nuance helps. Even when gene testing is done properly, it does not always find two clear variants. Clinical guidance addresses this gap directly. If molecular testing finds no or only one faulty variant, measuring reduced enzyme activity on a liver biopsy can still establish the diagnosis in older pathways. That is why doctors combine gene results with biochemical evidence rather than reading DNA in isolation.

For you, the reassuring reading is direct. A single carrier result on a DTC panel means you are healthy with respect to this disease. Two next steps are genuinely useful. First, understanding your partner’s carrier status helps with any future family planning. Second, mentioning your brother’s recurrent stones to a clinician is worthwhile, because undiagnosed primary hyperoxaluria can appear as adult stone disease. Confirming any concerning DTC result through a clinical genetics or nephrology visit is always wise; a genetic counselor can arrange it.

Section recap: Carrier is not diagnosis, and an uncertain variant is not proof of disease. Your single carrier result means you are healthy for this condition.

Prevention, Early Detection, and Everyday Oxalate Management

The underlying gene defect cannot be changed. So evidence-based care focuses on catching problems early and reducing the oxalate load on the kidneys. This section applies mainly to someone actually diagnosed, not to a healthy carrier. Still, it helps you understand what care looks like if a relative turns out to be affected.

Clinical reviews describe several supportive measures used under specialist guidance:

• High fluid intake — keeps urine dilute so crystals are less likely to form; doctors often target a large daily urine volume spread across day and night.
• Oral citrate (often potassium citrate), sometimes magnesium — inhibits calcium-oxalate crystals by making them less likely to clump.
• Vitamin B6 (pyridoxine) — helps a subset of patients; the response is well established in some PH1 cases and less certain in PH2.
• Diet changes around oxalate and calcium — considered only under specialist guidance, since cutting calcium the wrong way can backfire.

Imagine flushing a drain often so debris never settles: that is the logic behind steady fluids and crystal inhibitors. A word of caution fits here. These measures support the kidneys but do not fix the gene, and self-directed megadoses of supplements can do harm. The right doses, targets, and combinations are set by a specialist for the individual patient. That is another reason a healthy carrier does not need to start any of this.

Early detection deserves special emphasis, because it changes the whole trajectory. When the disease is caught before major kidney damage, monitoring can track function over time and prompt treatment before crystals scar the kidney. When it is caught late, oxalate may already be depositing beyond the kidneys, the systemic oxalosis noted earlier, which is much harder to reverse. Natural-history cohorts make this contrast concrete: how early the disease is recognized is among the strongest predictors of long-term kidney survival. An everyday parallel is dental care: routine check-ups catch a small cavity early, while ignoring pain until a tooth cracks makes repair far harder.

Regular nephrology follow-up matters most. Studies show that routine imaging and kidney-function checks catch early damage, such as calcium deposits in the kidney (nephrocalcinosis), before it worsens. Registry data also link higher urinary oxalate to faster loss of kidney function, which is exactly why lowering oxalate is a core treatment target. For context on how serious untreated disease can become, one registry found that most PH1 patients reached kidney failure by age 60, underscoring that timing changes lives.

In advanced disease, oxalate spreads beyond the kidneys into other organs, a state called systemic oxalosis. The large PH2 cohort is a sobering reminder that this type is not benign: about a fifth of those patients reached advanced kidney failure over years of follow-up. Anyone diagnosed should build a monitoring plan with a nephrologist, not manage this alone. A genetic counselor at NSGC.org can also help a family understand who should be watched.

Section recap: Since the gene cannot be fixed, care centers on fluids, crystal inhibitors, and early monitoring. Cohort data show early recognition strongly improves outcomes.

The Modern Treatment Landscape: RNAi Drugs, Citrate, Dialysis, and Transplant

The treatment story has changed a lot, and headlines about “RNA kidney-stone drugs” refer to two real medicines. The honest details matter, so read this section carefully. Both drugs are approved for type 1 (PH1), the AGXT form, and not for the GRHPR (type 2) form your report flagged. Here is the dated picture at a glance:

Drug (brand)	What it targets	FDA approval	Approved subtype
Lumasiran (Oxlumo)	glycolate oxidase (an RNAi drug)	November 23, 2020	PH1 only
Nedosiran (Rivfloza)	lactate dehydrogenase (gene-silencing)	September 29, 2023	PH1 only, age 9+

Health Canada status. Health Canada’s approval status for these RNAi therapies may differ from the FDA’s and should be confirmed against current Health Canada listings; this article does not assert a Canadian approval date. Because you live in Toronto, that distinction matters: a drug’s US approval does not automatically mean the same approval or the same conditions in Canada, and regulatory status can change over time. A nephrologist or specialist center can tell you what is currently available and approved in Canada.

Lumasiran, sold as Oxlumo, is an RNA interference drug. It lowers oxalate production by targeting an enzyme called glycolate oxidase. The US Food and Drug Administration approved it on November 23, 2020, for primary hyperoxaluria type 1. It was the first FDA-approved therapy for PH1 and is given as an injection under the skin. A phase 3 trial, called ILLUMINATE-A, randomized 39 PH1 patients to the drug or placebo for six months. It reduced 24-hour urinary oxalate by about 65%, with an effect visible as early as the first month, and enrolled PH1 patients only.

Nedosiran, sold as Rivfloza, is a related type of gene-silencing drug. It targets a downstream enzyme, lactate dehydrogenase. The FDA approved it on September 29, 2023, for people aged 9 and older with primary hyperoxaluria type 1 and relatively preserved kidney function. Its approved label and pivotal evidence center on PH1.

Here is the point most articles blur. Because nedosiran hits a shared downstream step, its mechanism is theoretically relevant to PH2 and PH3. But “theoretically relevant” is not “proven to work.” A pivotal trial called PHYOX2 randomized 35 people, 29 with PH1 and only 6 with PH2, to the drug or placebo for six months. Overall, the drug beat placebo, and its benefit was strongest in the PH1 subgroup. Crucially, that trial found no consistent oxalate-lowering effect in the small PH2 subgroup. So efficacy in PH2 is not established, despite the shared mechanism. These are not “PH2 drugs.”

Why does the subtype matter so much for candidacy? Registry data show that in PH1, kidney damage often builds steadily, with most patients reaching kidney failure by later adulthood if untreated. In absolute terms, one natural-history registry reported that roughly 57 of every 100 PH1 patients had reached end-stage kidney disease by age 40. Lowering oxalate is the lever these drugs pull, and higher oxalate tracks with faster decline. That is the logic behind treating PH1 aggressively. For PH2, which tends to be milder, the same drugs have simply not shown the same proven benefit yet.

Conventional care still matters in advanced disease. Intensive dialysis can help clear oxalate from the blood when the kidneys cannot. Combined or sequential liver-kidney transplantation has been used, historically for PH1, because replacing the liver can correct the source of overproduction. These are major interventions weighed carefully against their risks. All drug and transplant decisions are individualized and made by a nephrology or metabolic team, never by a web article. If a relative is diagnosed, a specialist center is the right place to discuss these options.

Section recap: Lumasiran (FDA 2020-11-23) and nedosiran (FDA 2023-09-29) are approved for PH1 only; their Canadian status must be confirmed with Health Canada. In a small PH2 subgroup, no consistent benefit was seen, so PH2 use is unproven.

Family Implications: Partner Testing, Cascade Screening, and the Sibling With Stones

Because PH2 is recessive, your result carries real meaning for relatives. This spread-out testing across relatives is called cascade screening; it is a way to find carriers before surprises happen. For a single carrier like you, the inheritance odds for close relatives are fixed:

• Each of your siblings has a 50% chance of also being a carrier.
• Each of your biological children has a 50% chance of inheriting your variant.
• Your children can be affected only if your partner also carries a GRHPR variant.

Two steps are most actionable for you. First, if you plan more children, knowing your reproductive partner’s GRHPR status clarifies the real odds. If your partner does not carry a GRHPR variant, your children cannot inherit two faulty copies from the two of you, so none would be affected by this route. Second, flagging your brother’s recurrent kidney stones is genuinely worthwhile. Two faulty copies could mean an undiagnosed case that would benefit from proper evaluation, since adults with recurrent stones can go undiagnosed. The gap between genetic and clinical prevalence suggests exactly this pattern of missed adult cases. Encourage him to see a nephrologist; a specialist can order the right tests.

Known carrier couples have several options to discuss with a clinician:

• Expanded carrier screening before pregnancy
• Prenatal diagnosis during pregnancy
• Preimplantation genetic testing (PGT-M), which screens embryos before pregnancy

These are personal decisions, not obligations. Think of cascade testing like sharing a weather forecast with family: the information helps them prepare, but each person chooses what to do with it.

There is a genuinely hopeful angle here too. If your brother does turn out to have undiagnosed PH2, finding out is not just a label. Cohort evidence shows outcomes depend heavily on early recognition and monitoring, so a diagnosis opens the door to fluids, crystal inhibitors, and specialist follow-up that protect the kidneys. A rare-disease resource likewise points families toward specialist and genetic-counseling referral rather than leaving them to guess. A board-certified genetic counselor, found through the Find a Genetic Counselor tool at NSGC.org, can map who might benefit from testing without causing alarm.

Section recap: Each sibling and child of a carrier has a 50% chance of carrying the variant. Partner testing and evaluating your brother’s stones are the most useful next steps.

Psychosocial and Legal Context: GINA, Insurance Gaps, and Telling Relatives

Insurance worries are common and reasonable, so here are the facts. In the US, the Genetic Information Nondiscrimination Act, known as GINA, was passed in 2008. What it does and does not cover matters before you apply for anything:

• Covered by GINA: health insurance (coverage, premiums) and employment (hiring, firing).
• NOT covered by GINA: life insurance, disability insurance, and long-term-care insurance.
• Extra state protection: some states, such as California, extend protections further, but the federal gap remains.

The Affordable Care Act separately bars health-plan discrimination for pre-existing conditions. That uncovered gap is exactly the one on your mind, since you are weighing a life-insurance application. Think of GINA as a fence around your health coverage and job, with the life-and-disability yard left outside it. This is educational context about the law, not advice on your specific policy.

You live in Toronto, so Canadian law is directly relevant. Canada’s federal Genetic Non-Discrimination Act, passed in 2017, is broader. It prohibits requiring anyone to undergo or disclose genetic test results as a condition of a contract or of accessing goods or services, including insurance. On July 10, 2020, the Supreme Court of Canada upheld this law as constitutional. Provincial health plans, such as Ontario’s OHIP, cover medically indicated diagnostic testing. This gives Canadian residents broader protection than US GINA.

The timing of testing and insurance can interact, which is why people weigh order carefully. In the US, some choose to settle life or disability coverage before pursuing genetic testing that GINA does not shield. In Canada, the broader 2017 law reduces that pressure, since it bars requiring or disclosing test results to access insurance. Neither situation is a reason to avoid medically needed diagnostic testing, which provincial plans like OHIP cover. The tradeoffs differ by person and country, so a professional review beats guesswork.

The emotional side matters too. Telling siblings you are a carrier can feel awkward, especially a brother with unexplained recurrent stones. Framing it as useful medical and reproductive information, rather than bad news, often helps. Remember that each sibling has a 50% chance of carrying the same variant, so the information is genuinely relevant to them. This article is educational context, not legal or medical advice. A genetic counselor at NSGC.org can help you navigate disclosure decisions and any insurance timing questions with a professional.

Section recap: US GINA protects health coverage and jobs but not life, disability, or long-term-care insurance. Canada’s 2017 law, upheld in 2020, is broader.

Frequently Asked Questions

Q: I’m a GRHPR carrier on 23andMe. Does that mean I have primary hyperoxaluria? A: No. A single GRHPR variant makes you an unaffected carrier. A PH2 diagnosis requires two faulty copies plus lab evidence of excess oxalate. Being a carrier does not put your own kidneys at risk. Confirm any concerning result with a clinician.

Q: Will my children inherit primary hyperoxaluria because I’m a carrier? A: Only if your reproductive partner is also a GRHPR carrier. In that case, each pregnancy has a 25% chance of an affected child, about 25 out of 100. Partner testing is the key next step, and a genetic counselor can arrange it.

Q: Will a genetic result affect my health or life insurance? A: In the US, GINA protects health insurance and employment but not life, disability, or long-term-care insurance. In Canada, the 2017 Genetic Non-Discrimination Act, upheld in 2020, is broader. Know the gap before you apply.

Q: Can my employer find out about my carrier status? A: In the US, GINA prohibits employers from using genetic information in hiring or firing decisions. In Canada, the federal law bars requiring or disclosing genetic test results to access contracts or services. For specifics, ask a genetic counselor or a qualified professional.

Q: Should I get a second opinion or confirm this result? A: Yes. DTC panels test a limited set of variants and are not diagnostic. A CLIA-certified US lab or an accredited Canadian lab can confirm concerning results. A nephrologist or a genetic counselor at NSGC.org can guide the right path.

Summary

A single GRHPR variant on a 23andMe report makes you a carrier, not a patient. Research is clear that primary hyperoxaluria is autosomal recessive and needs two faulty copies to cause disease. Your own kidney risk from one variant is essentially zero. The 25% recurrence figure applies only when both partners carry a GRHPR variant. The disease itself is rare, on the order of 1 to 3 per million, and likely underdiagnosed.

The most useful actions are practical. Confirm concerning DTC results through certified clinical testing. Consider your partner’s carrier status for family planning. Encourage your brother to have his recurrent stones evaluated. On treatment, be precise. Lumasiran (Oxlumo, FDA 2020-11-23) and nedosiran (Rivfloza, FDA 2023-09-29) are approved for type 1 only. Their Health Canada status may differ from the FDA’s and should be confirmed against current Canadian listings; this article does not assert a Canadian approval date. A small PH2 subgroup in a pivotal trial showed no consistent benefit, so these are not proven PH2 drugs. For any real decision, a nephrologist and a genetic counselor are the right guides, not a web page.

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

References

1. NIH MedlinePlus Genetics (National Library of Medicine). Primary hyperoxaluria: MedlinePlus Genetics. https://medlineplus.gov/genetics/condition/primary-hyperoxaluria/
2. Milliner DS, Harris PC, Sas DJ, Cogal AG, Lieske JC. Primary Hyperoxaluria Type 2. GeneReviews, NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK2692/
3. Online Mendelian Inheritance in Man (OMIM), Johns Hopkins University. #260000 Hyperoxaluria, Primary, Type II; HP2. https://omim.org/entry/260000
4. Garrelfs SF, et al. (2019) Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up. Kidney International (OxalEurope Consortium). https://pubmed.ncbi.nlm.nih.gov/31685312/
5. Zhao F, Bergstralh EJ, Mehta RA, et al. (2016) Predictors of Incident ESRD among Patients with Primary Hyperoxaluria. Clinical Journal of the American Society of Nephrology / Rare Kidney Stone Consortium PH Registry. https://clinicaltrials.gov/study/NCT00588562
6. Groothoff JW / Sas DJ, et al. (2025) Global genetic prevalence estimates of primary hyperoxaluria are greater than previously reported. Clinical Kidney Journal 18(7):sfaf194. https://academic.oup.com/ckj/article/18/7/sfaf194/8168204
7. U.S. Food and Drug Administration / Alnylam Pharmaceuticals. OXLUMO (lumasiran) – FDA approval for Primary Hyperoxaluria Type 1. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214103
8. U.S. Food and Drug Administration / Novo Nordisk (Dicerna). RIVFLOZA (nedosiran) – FDA approval for Primary Hyperoxaluria Type 1. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215842
9. Garrelfs SF, et al. (2021) Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. New England Journal of Medicine 384:1216-1226 (ILLUMINATE-A). https://pubmed.ncbi.nlm.nih.gov/33789010/
10. Hoppe B, et al. (2022) PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2. Kidney International 102(3):642-651. https://pubmed.ncbi.nlm.nih.gov/36007597/
11. Richards S, Aziz N, Bale S, et al. (2015) Standards and Guidelines for the Interpretation of Sequence Variants. Genetics in Medicine 17(5):405-424 (ACMG/AMP). https://www.gimjournal.org/article/S1098-3600(21)02771-2/fulltext
12. National Human Genome Research Institute (NHGRI), NIH. Genetic Discrimination and the Genetic Information Nondiscrimination Act (GINA). https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination
13. Supreme Court of Canada, Reference re Genetic Non-Discrimination Act, 2020 SCC 17. https://www.canlii.org/en/ca/scc/doc/2020/2020scc17/2020scc17.html
14. National Organization for Rare Disorders (NORD). Primary Hyperoxaluria – NORD Rare Disease Database. https://rarediseases.org/rare-diseases/primary-hyperoxaluria/

---

Last updated: 2026-08-08

Author: genelumen editorial team. This article aggregates 14 sources from peer-reviewed medical literature and public health agencies (tier 1=10 / tier 2=3 / tier 3=1), including NIH, MedlinePlus, OMIM, FDA regulatory records, ACMG guidelines, and PubMed-indexed publications.

This article is for educational purposes only and is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911 (US/Canada) or 119 (Japan).

Related: Genetic Diseases category

🌐 日本語版: https://genelumen.com/ja/ja-metabolic-hematologic-genetic/primary-hyperoxaluria-type2-grhpr-inheritance